Last reviewed · How we verify
Fludeoxyglucose F-18 (F-18)
Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions.
At a glance
| Generic name | F-18 |
|---|---|
| Also known as | F-18 THK-5351, F-18 AV-45, F-18 PMPBB3 |
| Sponsor | 3D Imaging Drug |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2015 |
Mechanism of action
Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism. In comparison to background activity of the spe
Approved indications
- Oncology
- Cardiology
- Neurology
- malignancy
- coronary artery disease
- left ventricular dysfunction
- epileptic seizures
- cancer
- abnormal glucose metabolism
- coronary artery disease and left ventricular dysfunction
Common side effects
- Hypersensitivity reactions
- Pruritus
- Edema
- Rash
Key clinical trials
- FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (PHASE2)
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin (PHASE1)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (PHASE1,PHASE2)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludeoxyglucose F-18 CI brief — competitive landscape report
- Fludeoxyglucose F-18 updates RSS · CI watch RSS
- 3D Imaging Drug portfolio CI